Quality by Design & Pharmaceutical Development
Quality by Design (QbD) is a systematic approach to development that begins with predefined objectives and emphasises product and process understanding and process control, founded on sound science and quality risk management. Articulated across ICH Q8, Q9 and Q10, it reframes quality as something designed into a product — not inspected into it at the end of the line.
Build quality in, don’t test it in
The old model tested quality at the end: make the batch, test a sample, release or reject. QbD inverts that. It starts from the Quality Target Product Profile (QTPP) — what the product must do for the patient — and works backwards to a process designed to deliver it every time. Testing then confirms a controlled process rather than substituting for one.
ICH Q8 (Pharmaceutical Development) is where this understanding is built and documented. The design space and control strategy it produces give room to adjust within validated limits without a new submission — and a science-based answer when a regulator asks why the process looks the way it does.
CQAs, CPPs, and the design space
Two definitions do the heavy lifting. A Critical Quality Attribute (CQA) is a property that must be controlled within a limit to ensure product quality; a Critical Process Parameter (CPP) is an input whose variability affects a CQA. QbD is, in essence, understanding which CPPs drive which CQAs, and by how much.
That understanding defines a design space: the multidimensional combination of inputs and parameters shown to assure quality. Working within the approved design space is not considered a change and does not trigger a post-approval regulatory filing — one of QbD’s most practical regulatory benefits, giving manufacturers room to adjust without re-approval.
The control strategy is the output
Process understanding is only useful if it becomes control. QbD converges on a control strategy — the planned set of controls, derived from product and process understanding, that assures process performance and product quality. It spans input material controls, process controls, in-process and release testing, and the monitoring that keeps the process inside its design space. This is the bridge from development to process validation.
QbD, risk management, and the quality system
ICH Q8 does not stand alone. Quality risk management (ICH Q9) is how you decide which attributes and parameters are critical and where to focus effort; the Pharmaceutical Quality System (ICH Q10) is what sustains the design and control strategy across the lifecycle. Together the three guidelines are the modern operating model for pharmaceutical quality — QbD is the development half of it.
Derived from the 4 standards that anchor this topic.
What is Quality by Design (QbD)?
A systematic, science- and risk-based approach to pharmaceutical development that starts from predefined objectives (the Quality Target Product Profile) and emphasises product and process understanding and control — designing quality into the product rather than testing it in. It is described in ICH Q8.
What is a design space?
The multidimensional combination of input variables and process parameters demonstrated to provide assurance of quality. Working within an approved design space is not considered a change and does not require a post-approval regulatory filing — a key practical benefit of QbD.
What is the difference between a CQA and a CPP?
A Critical Quality Attribute (CQA) is a product property that must stay within limits to ensure quality (e.g. purity, dissolution). A Critical Process Parameter (CPP) is a process input whose variability affects a CQA. QbD is largely about understanding which CPPs drive which CQAs.
Is QbD mandatory?
QbD is an expectation and a framework (ICH Q8/Q9/Q10), not a single binding rule — a fully traditional development approach is still permitted. But regulators increasingly expect the process understanding QbD produces, and the design-space flexibility is only available if you do the QbD work.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.